RIFAMPICIN FAILURE

Ying Zhang (Johns Hopkins Bloomberg School of Public Health. Baltimore) and his team have described for the first time a variant of M. tuberculosis present in a 35 years old chinese who grew up instead of dying after treatment with rifampicin (RFP). When RFP was retired the patient improved, as it was reported in the International Tuberculosis Lung Disease (2009. An interesting case of rifampicin-dependent/enhanced MDR-TB). Currently, 5% of TB does not respond to RFP or Isoniazid, 2 of the most important drugs in the fight against Tuberculosis, a fact attributable to prolonged administration of drugs and neglect to ingest the drug, factors that favour the emergence of resistant strains.

FALLAS DE LA RIFAMPICINA

Ying Zhang (Johns Hopkins Bloomberg School of Public Health. Baltimore) y su equipo han descrito por primera véz, una variante de M tuberculosis presente en un chino de 35 años, que en véz de morir creció tras el tratamiento con Rifampicina (RFP). Al retirársele la RFP, el paciente mejoró, según reporta el International Tuberculosis Lung Disease (2009. An interesting case of rifampin-dependent/enhanced MDR-TB). Actualmente, 5% de tuberculosos no responde ni a RFP ni a Isoniazida, 2 de los agentes más importantes en la lucha contra la TBC, un hecho atribuible al tiempo prolongado de la administración de los medicamentos y el abandono de los mismos que favorecen la emergencia de cepas resistentes.